相关实验视频
Updated: May 5, 2026
10:33
Generation of Alginate Microspheres for Biomedical Applications
Published on: August 12, 2012
20.7K
用于药物输送应用的海藻多糖:一项审查
Nada E Ramadan1, Fatma R Youssef1, Amira A K Alshishtawy2
1Department of Biotechnology, Faculty of Science, Tanta University, Egypt.
International journal of biological macromolecules
|January 8, 2025
概括
海藻多糖因其生物相容性和治疗性质而提供安全有效的药物递送系统 (DDS). 这些天然聚合物是开发先进纳米粒子,水凝和薄膜治疗严重疾病的关键.
科学领域:
- 生物材料科学 生物材料科学
- 聚合物化学 聚合物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多糖因其生物活性,包括无毒性,生物降解性和治疗潜力而受到越来越多的关注.
- 海洋藻类衍生的多糖具有多样性的特性,使其适合创新的应用.
- 这些特性对开发先进的药物输送系统 (DDS) 特别有希望.
研究的目的:
- 审查海藻多糖在药物输送系统中的优势和应用.
- 总结一下利用这些天然聚合物的药物输送技术的最新进展.
- 为未来研究基于藻类多糖的药物输送提供见解.
主要方法:
- 关于海洋藻类多糖和药物输送系统的科学出版物的文献综述.
- 对各种藻类多糖的特性和生物活性进行分析.
- 基于藻类多糖的不同类型的药物输送系统 (纳米粒子,微球,水凝,贴片,薄膜) 的分类.
主要成果:
- 海藻多糖是用于构建各种药物递送系统 (DDS) 的多功能生物材料.
- 这些DDS表明可以控制和持续释放治疗剂,显示抗炎和抗癌潜力.
- 应用范围包括再生医学,基因传递和针对严重疾病的向治疗.
结论:
- 海洋藻类的多糖为开发安全,有效和环保的药物输送系统提供了宝贵的资源.
- 它们的独特特性促进了受控释放和治疗效益,解决了医学中的关键需求.
- 对基于藻类多糖的DDS的进一步研究对未来的治疗创新具有重大前景.
相关概念视频
01:16Drug Delivery: Overview
1.3K
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
1.3K
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
01:23Modified-Release Drug Delivery Systems: Classification
315
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
315
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
177
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
177
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
01:11Oral Drug Delivery Systems: Delayed-Release Systems
222
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
222